Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease

Javier E. Banchs, Giselle A. Baquero, Michelle J. Nickolaus, Deborah Wolbrette, John Kelleman, Soraya Samii, Jennifer Grando-Ting, Erica Penny-Peterson, William Davidson, Sallie K. Young, Gerald Naccarelli, Mario Gonzalez

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Background: Atrial tachyarrhythmias (AT) including atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia represent a clinical challenge in the adult with congenital heart disease (CHD). Dofetilide (D) is a rapidly activating delayed rectifier potassium channel (IKr) blocker effective in pharmacological conversion and maintenance of normal sinus rhythm in patients with AF and AFL. There is limited knowledge regarding the role of D in adults with CHD. Methods: Safety and efficacy of D was evaluated in a consecutive group of thirteen adult patients (age 40 ± 11; six women) with CHD and refractory AT. Results: Ten patients had persistent (four AFL, one AF, and five atrial tachycardia) and three paroxysmal (one AF and two atrial tachycardia) AT. All patients were symptomatic during tachycardia, 12 patients had previously failed 2 ± 1 antiarrhythmic drugs. Mean systemic ventricular ejection fraction was 55 ± 9%; baseline QRS complex duration was 129 ± 45ms (>120ms in six patients). Patients were followed on D for 33 ± 39 months (median 16). Among 10 patients with persistent AT, seven patients (70%) pharmacologically converted to sinus rhythm on D and three patients (30%) required direct current cardioversion. Two patients (15.4%) experienced complete arrhythmia suppression, and seven (53.8%) experienced significant clinical improvement with sporadic recurrences; average time to recurrence was 5.5 ± 3.5 months. One patient developed torsade de pointes during loading, and the drug was discontinued. D was discontinued in five (38.5%) other patients due to recurrence of AT (n = 4) and renal failure (n = 1). Corrected QT interval (QTc) increased from 452 ± 61 to 480 ± 49ms (P = .04) and corrected JT interval (JTc) from 323 ± 39 to 341 ± 33ms (P = .09). Conclusions: D should be considered a pharmacologic alternative when adult patients with CHD develop AT. D does not depress conduction, sinus node, or ventricular function but needs close monitoring for potential ventricular pro-arrhythmia.

Original languageEnglish (US)
Pages (from-to)221-227
Number of pages7
JournalCongenital Heart Disease
Issue number3
StatePublished - Jan 1 2014

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease'. Together they form a unique fingerprint.

Cite this